We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




EU Data Protection Regulation May Put European Cancer Research at Risk

By LabMedica International staff writers
Posted on 05 Aug 2014
Print article
A European oncologic society’s members are worried that a proposed European Union (EU) data protection regulation could make cancer research unfeasible and add a substantial burden to both physicians and cancer patients.

The European Society of Medical Oncology (ESMO; Lugano, Switzerland) has expressed concern that the proposed EU General Data Protection Regulation, published in the August 2014 issue of the journal Annals of Oncology, could make cancer research impossible. The planned wording of the regulation stipulates “explicit and specific patient consent,” meaning that researchers would have to approach patients every time research is arranged to refer to their data or use tissue samples stored for research purposes.

“Hope for patients facing a life-threatening disease like cancer is based on advances in research,” said Kathy Oliver, chair of the International Brain Tumor Alliance. “And research progress requires access to a wide pool of patient data, even from patients who have since passed away and can no longer provide consent to allow for research that could save lives in the future.”

“This could put a halt to many public health research efforts,” said ESMO president Rolf A. Stahel. ESMO proposes that the text of the EU General Data Protection Regulation includes a “one-time consent” for research, ensuring patients are aware of what they are consenting to—with the suitable safeguards in place, and that they can withdraw their consent at any time. “Our proposal achieves the correct balance between the right to privacy and the right to health. It actually empowers patients, allowing them to choose whether to donate their data and tissue for public health research, which has the ultimate goal of finding cures.”

“As a cancer patient, I cannot think of any reason not to allow access to my data to help other patients receive better care and contribute to advancing cancer research,” noted Hans Keulen, a Dutch rare cancer patient from the Chordoma Foundation (Durham, NC, USA).

Dr. Paolo G. Casali, ESMO Public Policy committee chair, author of the official ESMO position paper on the risks of the new EU Data Protection Regulation, said, “We understand the need for the EU to address data privacy concerns in many sectors, with the surge of risks brought about by the use of digital information, but its effect on public health research may have been unintentionally overlooked.”

Population-based cancer registries, for example, storing information to track disease trends, are inherently incompatible with any requirement of individual consent, “If a patient is allowed not to consent use of his/her anonymized data for the registry, the data provided by that registry will be unrepresentative and can lead to incorrect conclusions for public health actions,” noted Dr. Casali.

ESMO is in favor of inclusion in the EU General Data Protection Regulation of the withdrawable “one-time consent” strategy—already forecast in the Clinical Trials Regulation adopted by the European Union in 2014, which allows to use data already stored beyond the end and the specific scope of a trial, with the usual strict safeguards. ESMO spokespersons stated, “We are calling upon the European Union to assure that all forms of public health research will survive and be able to function within the safeguards that are in place, without adding the nearly impossible administrative burden of re-consenting each patient, every time, for every single project, which could irreversibly slow down the accelerated pace that cancer research has gained over the past decades.”

Related Links:

European Society of Medical Oncology


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.